ImmunityBio to Work with BeiGene on Confirmatory Phase 3 Lung Cancer Trial

 

• Confirmatory trial builds on results of QUILT 3.055, a Phase 2 trial demonstrating ANKTIVA rescued T cells and activity of checkpoint inhibitors (CPIs) in patients with non-small cell lung cancer (NSCLC), who progressed on CPI therapies
• QUILT 3.055 showed prolonged overall survival in these second- and third-line NSCLC patients exceeding historical survival rates following chemotherapy
• ImmunityBio anticipates submitting a biologics license application (BLA) in 2025 for this indication based on the QUILT 3.055 data
• The ImmunityBio patent for ANKTIVA and CPI combinations extends to 2035

https://www.businesswire.com/news/home/20250129629819/en/